ABC News medical correspondent Dr. Darien Sutton answers your health questions and shares what you should eat after having a stomach bug.

January places a premium on health and wellness. We make New Year's resolutions to follow the Mediterranean diet and become a ...

The vaccine has shown over 90% efficacy across all age groups in the prevention of shingles, a painful and potentially serious disease that affects 1 in 3 people in the United States.

-- One year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix SEATTLE, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine ...

Older adults are advised to protect themselves from flu and shingles, but is offering adjuvanted ... Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window ...

Don't Miss Our New Year's Offers: Discover the latest stocks ... the enrollment for the Phase III clinical trial of its new shingles vaccine, REC610. This vaccine, designed for adults over 40 ...

Scientists have developed a vaccine for shingles, the unpleasant and often ... and it is increasingly affecting younger people. The new injection is similar to a vaccine that has been developed ...

Opens in a new tab or window Share on Bluesky ... “We performed this study using data from live attenuated vaccine for shingles, which is no longer available in the United States,” he said.

Shingrix in 2017 received US FDA approval to prevent shingles in adults aged 50 and older. Since 2021, it has been approved for use in immunocompromised patients aged 18 and up. GSK estimates around ...

So, we decided against giving me the shingles vaccine ... This is not the case with the new recombinant vaccine, Shingrix, which I strongly recommend for you. Another reader asked whether the ...

(IN BRIEF) GSK has announced that the FDA has accepted its application to review a prefilled syringe version of Shingrix, its shingles vaccine. This new version, expected to be available from January ...

-- One year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix SEATTLE, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine ...